Agilent Technologies And SISCAPA Assay Technologies Provide Complete Solution For Targeted Multiplexed Protein Quantitation To Enhance Customer Workflows

Agilent Technologies Inc. (NYSE:A) and SISCAPA Assay Technologies (SAT) today announced they have signed a non-exclusive agreement to enable SAT to provide an end-to-end solution for multiplexed protein quantitation using a highly automated workflow for SISCAPA LC-mass spectrometry. This solution will combine SAT’s reagents for targeted protein quantitation with Agilent’s Bravo Automated Liquid Handling Platform for sample preparation, along with liquid chromatography–mass spectrometers (LC/MS) for quantitative analysis. The agreement expands on an established strategic relationship between Agilent and SAT, furthering both companies’ ability to enhance customer workflows.

SAT will provide an integrated solution for targeted protein measurement. A protocol for addition-only trypsin digestion followed by anti-peptide immunocapture enrichment has been developed for the Bravo platform and is complemented by a purpose-designed, intuitive software interface. The process supports preparation of 400 multiplexed samples per working day, with sensitive and selective mass analysis carried out using Agilent’s triple quadrupole mass spectrometry instruments.

SISCAPA assays alleviate challenges of limited specificity and protein interferences seen with ligand binding assays and anti-protein immunocapture mass spectrometry. Subjecting the sample to up-front tryptic digestion and enriching for proteotypic peptides means SISCAPA assays measure the amount of a protein target in a highly multiplexed and high-throughput manner, free of such interferences. This greatly decreases the bottleneck of screening candidate protein biomarkers in clinical research.

“Agilent is a leader in workflow solutions, including high-precision sample preparation systems and rugged, sensitive LC/MS systems, and this partnership offers customers a truly enabling workflow to execute targeted protein assays with a throughput and precision that were previously impossible,” said Yvonne Linney, vice president and general manager for Agilent’s Life Science Solutions Division, which includes Automation and LC/MS businesses. “Agilent is pleased to partner with SISCAPA Assay Technologies, the leader in targeted protein quantitation, to offer researchers an integrated solution with simplified user interface, high-precision, sensitive quantitation and enhanced productivity.”

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis